laitimes

How does Puli Pharmaceutical protect its rights, issue an announcement on the progress of the investigation and risks, and collect claims

How does Puli Pharmaceutical protect its rights, issue an announcement on the progress of the investigation and risks, and collect claims

Puli Pharmaceutical's latest claim news:

On August 6, 2024, Hainan Puli Pharmaceutical Co., Ltd. issued the "Announcement on the Progress of Case Filing and Investigation and Risk Warning", which shows:

1. On July 5, 2024, Hainan Puli Pharmaceutical Co., Ltd. (hereinafter referred to as "Puli Pharmaceutical" or "the Company") disclosed the "Announcement on the Correction and Retrospective Adjustment of Accounting Errors in the Previous Period" (Announcement No.: 2024-083), the "2023 Annual Report" and the "Self-inspection and Rectification Report on the Decision of the Hainan Securities Regulatory Bureau to Take Corrective Measures against the Company" (Announcement No.: 2024-087) and other announcements on the information disclosure website designated by the China Securities Regulatory Commission.

2. The company's correction and retrospective adjustment of accounting errors in the previous period have not yet been comprehensively audited by the accounting firm or special assurance of the relevant corrections. As of the disclosure date of this announcement, the company and the accounting firm are making every effort to promote the relevant work. The Company will fulfill its information disclosure obligations in a timely manner according to the progress of relevant matters.

3. The company's 2023 audit institution, Tianjian Certified Public Accountants (Special General Partnership) (hereinafter referred to as "Tianjian Certified Public Accountants"), issued an audit report with a qualified opinion on the company's 2023 annual financial report. The main reservations involved are: First, because the company failed to provide a complete basis for the correction of the previous error, Tianjian Certified Public Accountants could not confirm whether the company's previous error correction was complete and whether the correction amount was accurate.

Prior to this, on July 8, 2024, Hainan Puli Pharmaceutical Co., Ltd. received the Notice of Case Filing from the China Securities Regulatory Commission for the second time (Zheng Jian Case No. 03720240024).

According to the Securities Law and the Several Provisions of the Supreme People's Court on the Trial of Civil Compensation Cases Arising from False Statements in the Securities Market, listed companies shall be liable for civil compensation if their rights and interests are damaged due to illegal information disclosure and misrepresentation, and the injured investors have the right to claim compensation for losses.

How does Puli Pharmaceutical protect its rights, issue an announcement on the progress of the investigation and risks, and collect claims

The reference conditions for the claim of Puli Pharma are as follows:

Those who bought 300630 Puli Pharmaceutical between April 26, 2022 and April 16, 2024, and sold or continued to hold it after April 17, 2024 (inclusive).

The above claim registration conditions only represent the views of the stock protection team, and are not used as any securities investment decisions and trading recommendations, and are subject to the final determination of the court.

Basis for Puli Pharmaceutical's violation:

On May 8, 2024, Puli Pharmaceutical Co., Ltd. disclosed the "Announcement on Receiving the Notice of Case Filing from the China Securities Regulatory Commission" (Announcement No.: 2024-044).

On July 8, 2024, Hainan Puli Pharmaceutical Co., Ltd. received the Notice of Case Filing from the China Securities Regulatory Commission (Zheng Jian Case No. 03720240024).

The current hot solicitation of shares is as follows:

300766 Daily Interaction, 000523 Guangzhou Langqi, 600289 Yiyang Information Communication, 002086 Donghai, 600589 Guangdong Rongtai, 600387 Haiyue Energy, 300427 Hongxiang Co., Ltd., 300078 Sichuang Yihui, 600771 Guangyuyuan, 600831 Radio and Television Network, 600185 Gree Real Estate, 000613 Dadonghai, 300585 Aolian Electronics, 000506 ST Zhongrun, 600748 SIIC Development, 000663 Yongan Forestry, 300526 Zhongqian Co., Ltd., 000802 Beijing Culture, 601101 Haohua Energy, 002471 Zhongchao Holdings, 300330 Huahong Jitong, 002569 Busen Co., Ltd., 002470 Jin Zhengda, 002656 Modern Avenue, 600343 Aerospace Power, 002235 Anne Co., Ltd., 601113 Huading Co., Ltd., 000700 Molding Technology, 300555 Lutong Shixin, 300310 Yitong Century, 000004 Guohua network security and so on.

Lawyer Xie Baoping has been engaged in securities misrepresentation claims for many years, has rich experience in handling misrepresentation cases, and the team of lawyers are all qualified to practice securities, and the successful cases are: Great Wisdom, Sanfangxiang, Jiayu Co., Ltd., EGing Optoelectronics, Baoli International, Sansheng Co., Ltd., Huifeng Co., Ltd., Jinan High-tech, Xiangyuan Culture, Zhonghe Co., Ltd., Selen Technology, Chaohua Technology, ST Rock, ISHUO Information, Zhongyida A Shares and B Shares, Tianshen Entertainment, Xiangyi Rongtong, Yabaite, Yan'an Bikang, Jinhua Co., Ltd., Changyuan Group, Shengleda, East Ocean, Feile Audio, Aoruide, Tianqi Shares, Huaze Retreat, Zhongbing Red Arrow..... More than 60 stocks.

How does Puli Pharmaceutical protect its rights, issue an announcement on the progress of the investigation and risks, and collect claims